DOI: 10.1055/s-00000075

Seminars in Respiratory and Critical Care Medicine

Referenz

Johnson and Johnson Pharmaceutical Research and Development.
FDA Issues Complete Response Letter for Ceftobiprole. 2009.
Available at:
http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=433517.Accessed 17 November, 2013

Bibliographische Angaben herunterladen

Suchen in: